129688-94-4

Upstream product

• 88-65-3 2-bromobenzoic-acid 
• 112734-22-2 4-bromo-2-fluorobenzylamine 
• 137643-14-2 2-(4-Bromo-2-fluoro-benzyl)-4-chlorocarbonylmethyl-1,3-dioxo-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid methyl ester 
• 142371-22-0 2-<(4-bromo-2-fluorophenyl)methyl>-4-(cyanomethyl)-1,2,3,4-tetrahydro-1,3-dioxo-4-isoquinolinecarboxylic acid methyl ester 
• 129688-82-0 2-<(4-bromo-2-fluorophenyl)methyl>-1,2,3,4-tetrahydro-4-(methoxycarbonyl)-1,3-dioxo-4-isoquinolineacetic acid 
• 129688-76-2 2-[(4-Bromo-2-fluorophenyl)methyl]-1,2,3,4-tetrahydro-4-(methoxycarbonyl)-1,3-dioxo-4-isoquinolineacetic Acid 1,1-Dimethylethyl Ester 
• 129688-70-6 2-[(4-Bromo-2-fluorophenyl)methyl]-1,2,3,4-tetrahydro-1,3-dioxo-4-isoquinoline-carboxylic Acid Methyl Ester 
• 129689-07-2 (2-Carboxyphenyl)propanedioic Acid Dimethyl Ester 
• 137643-17-5 2-(2-Chlorocarbonyl-phenyl)-malonic acid dimethyl ester 

Relevant academic research and scientific papers

Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-Bromo-2-fluorophenyl)methyl]-6- fluorospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone and congeners. 1

The high concentrations of plasma glucose formed during diabetic hyperglycemia rapidly translate into high levels of glucose in tissues where glucose uptake is independent of insulin. In these tissues that include the lens, retina, nerve, and kidney, this

N-substituted spirosuccinimide, spiropyridazine, spiroazetidine, and acetic acid aldose reductase inhibitors derived from isoquinoline-1,3- diones. 2

The isoquinoline-1,3-dione framework featured in our clinical candidate (1) and its congener was used as the template in the design of several new series of aldose reductase inhibitors (ARIs). These series included N'- substituted spirosuccinimide, spirop

ISOQUINOLINE ACETIC ACIDS AND ACETYL CARBAMATES USEFUL AS ALDOSE REDUCTASE INHIBITORS

This invention relates to isoquinoline acetic acids and acetyl carbamates and their pharmaceutically acceptable salts thereof, to processes for their preparation, to methods for using the compounds, and to pharmaceutical preparations thereof. The compounds have pharmaceutical properties which render them beneficial for thetreatment of diabetes mellitus and associated conditions

SPIRO-ISOQUINOLINE-PYRROLIDINE TETRONES AND ANALOGS THEREOF USEFUL AS ALDOSE REDUCTASE INHIBITORS

This invention relates to spiro-isoquinoline-pyrrolidine tetrones and their pharmaceutically acceptable salts thereof, to processes for their preparation, to methods for using the compounds, and to pharmaceutical preparations thereof. The compounds have pharmaceutical properties which render them beneficial for the prevention of diabetes mellitus associated complications